Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)
Status:
Recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the efficacy of magrolimab in combination
with azacitidine compared to that of azacitidine plus placebo in previously untreated
participants with intermediate/high/very high risk myelodysplastic syndrome (MDS) by Revised
International Prognostic Scoring System (IPSS-R) as measured by complete remission (CR) and
overall survival (OS).